The Economic Impact of Biosimilars

Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025.

EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability

Now Viewing

EP: 2.The Economic Impact of Biosimilars

EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars

EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars

EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption

EP: 6.Positioning Biosimilars in Clinical Practice

EP: 7.Assessing Patient Confidence With Biosimilars

EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars

Video content above is prompted by the following:

• Biosimilars have been shown to reduce costs to the US health system overall. What kind of savings are you seeing in your health system since fully implementing biosimilars?

Related Videos

Related Content

Advertisement

March 12th 2025

Frailty, Housing Instability Drive Mortality Risk in People With HIV

Brooke McCormick

These abstracts highlight the compounded challenges people with HIV face.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 11th 2025

Overdiagnosis of Adult ADHD Is Exacerbating the Stimulant Shortage

Salayna M. Abdallah, MA, BS Bryce L. Tipton, BS Joel W. Hughes, PhD

The authors argue that the stimulant shortage is being perpetuated by the overdiagnosis of attention-deficit/hyperactivity disorder (ADHD) in adults because executive functioning deficits are not included in diagnostic criteria.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 9th 2025

Reviving the Classics: The Role of Older Medications in Modern Dermatology

Brooke McCormick

Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.

March 9th 2025

Higher Dietary Fiber Intake Associated With Lower Osteoarthritis Risk

Brooke McCormick

A dietary fiber intake between 14.4 and 26.7 g reduced the risk of osteoarthritis, but an intake above this dose was not significantly protective.

Related Content

Advertisement

March 12th 2025

Frailty, Housing Instability Drive Mortality Risk in People With HIV

Brooke McCormick

These abstracts highlight the compounded challenges people with HIV face.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 11th 2025

Overdiagnosis of Adult ADHD Is Exacerbating the Stimulant Shortage

Salayna M. Abdallah, MA, BS Bryce L. Tipton, BS Joel W. Hughes, PhD

The authors argue that the stimulant shortage is being perpetuated by the overdiagnosis of attention-deficit/hyperactivity disorder (ADHD) in adults because executive functioning deficits are not included in diagnostic criteria.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 9th 2025

Reviving the Classics: The Role of Older Medications in Modern Dermatology

Brooke McCormick

Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.

March 9th 2025

Higher Dietary Fiber Intake Associated With Lower Osteoarthritis Risk

Brooke McCormick

A dietary fiber intake between 14.4 and 26.7 g reduced the risk of osteoarthritis, but an intake above this dose was not significantly protective.